Taro Pharmaceutical Industries Ltd
NYSE:TARO
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Price:
42.3 USD
-0.26%
Market Closed
Updated:
May 13, 2024
Taro Pharmaceutical Industries Ltd
Operating Expenses
|
Taro Pharmaceutical Industries Ltd
Operating Expenses Peer Comparison
Comparables:
T
TEVA
I
INCR
MDWD
R
REKA
C
CSURE
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Operating Expenses
-$271.3m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Operating Expenses
-$4.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Operating Expenses
-₪109.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
-26%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Operating Expenses
-$19.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Operating Expenses
-₪74.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
0%
|
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Operating Expenses
-₪6.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Taro Pharmaceutical Industries Ltd's Operating Expenses?
Operating Expenses
-271.3m
USD
-271.3m
USD
Based on the financial report for Dec 31, 2023, Taro Pharmaceutical Industries Ltd's Operating Expenses amounts to -271.3m USD.
What is Taro Pharmaceutical Industries Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-7%
-7%
Over the last year, the Operating Expenses growth was -13%. The average annual Operating Expenses growth rates for Taro Pharmaceutical Industries Ltd have been -20% over the past three years , -12% over the past five years , and -7% over the past ten years .
You don't have any saved screeners yet
